Bank Julius Baer & Co. Ltd Zurich Sells 1,845 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Bank Julius Baer & Co. Ltd Zurich trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 62.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,092 shares of the biopharmaceutical company’s stock after selling 1,845 shares during the period. Bank Julius Baer & Co. Ltd Zurich’s holdings in Regeneron Pharmaceuticals were worth $573,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in REGN. PGGM Investments increased its holdings in shares of Regeneron Pharmaceuticals by 159.7% during the 2nd quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock worth $44,308,000 after acquiring an additional 51,900 shares during the last quarter. Founders Capital Management LLC increased its stake in Regeneron Pharmaceuticals by 7.0% during the 2nd quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock worth $4,344,000 after acquiring an additional 538 shares during the period. Sepio Capital LP lifted its position in Regeneron Pharmaceuticals by 33.1% during the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company’s stock worth $2,150,000 after purchasing an additional 842 shares during the period. Generate Investment Management Ltd bought a new position in Regeneron Pharmaceuticals in the second quarter valued at approximately $6,300,000. Finally, Bellecapital International Ltd. increased its stake in shares of Regeneron Pharmaceuticals by 32.7% in the 2nd quarter. Bellecapital International Ltd. now owns 25,503 shares of the biopharmaceutical company’s stock valued at $13,389,000 after purchasing an additional 6,283 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Regeneron Pharmaceuticals

In other news, VP Jason Pitofsky sold 431 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the sale, the vice president directly owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Christine A. Poon sold 6,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares of the company’s stock, valued at $1,538,843.04. This trade represents a 73.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $755.90 on Friday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $800.99. The company has a fifty day moving average of $615.29 and a 200-day moving average of $575.72. The company has a market capitalization of $79.44 billion, a P/E ratio of 18.10, a P/E/G ratio of 2.03 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, beating the consensus estimate of $9.73 by $2.10. The company had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The firm’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter last year, the firm earned $12.46 EPS. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Thursday, November 20th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.43%.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on REGN. Redburn Atlantic upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, August 14th. Sanford C. Bernstein increased their price target on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a report on Wednesday, August 27th. BMO Capital Markets raised their price objective on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an “outperform” rating in a research note on Monday, August 4th. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday. Finally, Morgan Stanley cut their price target on shares of Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $776.81.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.